@Qingdao Sigma Chemicals
@janoshik
Clinical studies on
Retatrutide are wrapping up phase II -- results have been submitted to clinicaltrials.gov and once they're fully public, it should drive demand. Reports are that people lost, on average, 25% of bodyweight in 11 months. It's rather incredible that the worst result in the entire study was someone lost 5% of bodyweight (semaglutide and tirzepatide have about 10% of people not losing or still gaining weight). They've stated that they're definitely moving ahead with Phase III trials.
Also
orforglipron is a single GLP-1 agonist that is
not a peptide so it's supposed to be basically "semaglutide, but actually really cheap to produce". Studies on that are reported to be positive as well. It only has 48 carbons compared to the 187 carbons of semaglutide. And most of those are in rings so it's only 23 bonds long at the most, whereas semaglutide is super long with 3 different strings that are each like 40-60 bonds long. Oh, and I almost forgot to mention:
it's an oral pill. Doses will probably be somewhere between 2 and 16mg taken daily, but need to wait for Phase II results to be published to know more.
Mainstream policymakers strongly believe that both drugs will be approved by FDA, based on the preliminary data made public.
Any chance you can get these, at least as raws?